Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Sosei Group ( (JP:4565) ).
Nxera Pharma will receive a US$3.6 million milestone payment from Centessa Pharmaceuticals after Centessa achieved an early development milestone for ORX142, an investigational, orally administered orexin receptor 2 agonist being developed for neurological and neurodegenerative disorders. The payment, to be recognized as revenue in the fourth quarter of fiscal 2025, underscores the financial and strategic value of Nxera’s research collaborations and provides additional non-dilutive funding that supports its pipeline-focused business model and reinforces its position as a key partner in innovative neuroscience drug development.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen720.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
More about Sosei Group
Nxera Pharma is a technology-driven biopharmaceutical company focused on developing new specialty medicines to address unmet medical needs in Japan and globally. It operates an agile commercial business in Japan, marketing several innovative products to the domestic and broader Asia-Pacific markets, and advances an extensive pipeline using its proprietary NxWave GPCR structure-based drug discovery platform. The company collaborates with leading pharmaceutical and biotech partners and maintains operations in Japan, the UK, Switzerland and South Korea, with its shares listed on the Tokyo Stock Exchange under ticker 4565.
YTD Price Performance: 5.20%
Average Trading Volume: 913,645
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen78.73B
Find detailed analytics on 4565 stock on TipRanks’ Stock Analysis page.